Accessibility Menu
NuCana Plc logo

NuCana Plc(NASDAQ) NCNA

Market Cap$6.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-56%
1 Month+18%
$1.53
-1.29%
-0.02Today
NuCana Plc last closing stock price
MetricPriceDate
Last closeUSD 1.552026-08-19
NuCana Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.39%USD 1.432026-08-12
1 month+18.32%USD 1.312026-07-20
3 month-23.65%USD 2.032026-05-21
Year to date-56.94%USD 3.602025-12-31
1 year-56.46%USD 3.562025-08-19
3 year-99.96%USD 3,750.002023-08-18
5 year-99.98%USD 9,750.002021-08-20
Since inception-100%USD 80,750.002017-09-28

NuCana Plc Financials at a Glance

Market Cap

$6.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£9.73M

EPS (TTM)

-$3.22

P/E Ratio

-0.48

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$1.53

Volume

18,408

Open

$1.53

Previous Close

$1.53

Daily Range

$1.50 - $1.55

52-Week Range

$1.21 - $7.22

Estimated Earnings Date

Nov 12, 2026

NCNA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NuCana Plc

NuCana plc is a clinical-stage biopharmaceutical firm focused on developing advanced therapies for oncology. The company leverages its proprietary ProTide technology platform to create innovative drug candidates aimed at treating various types of cancer.

Products and Services
  • Acelarin: Undergoing multiple clinical trials for various cancers
  • NUC-3373: A ProTide derivative of 5-fluorouracil in Phase I and II trials
  • NUC-7738: A nucleoside analog in Phase 1/2 clinical assessment
Growth Outlook
  • Strong pipeline with multiple ongoing clinical trials for Acelarin
  • NUC-3373 shows promise in advanced colorectal cancer studies
  • Collaborations with Cardiff University enhance research capabilities
Financial Highlights
  • Cash and cash equivalents of approximately $21.5 million as of March 2026
  • Operating expenses totaled $4.4 million in Q1 2026
  • Net income loss of $3.9 million reported for Q1 2026
NuCana plc is positioned in the biotechnology sector, focusing on innovative cancer treatments. The company's ProTide technology platform is a key differentiator, enabling the development of drugs that may improve efficacy and reduce side effects compared to traditional therapies. The ongoing clinical trials for Acelarin and NUC-3373 are critical to the company's growth strategy, with potential to address significant unmet medical needs in oncology. Financially, the company maintains a solid cash position, which supports its research and development efforts. Despite recent losses, the focus on advancing its product pipeline and strategic collaborations suggests a commitment to long-term growth in the competitive biopharmaceutical landscape.
AI Generated • Aug 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

12

CEO

Hugh Stephen Griffith, MBA

Website

www.nucana.com

Headquarters

Edinburgh, MD EH12 9DT, GB

NCNA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-41.96%

Return on Capital

-80.43%

Return on Assets

-37.96%

Earnings Yield

-2.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.31M

Volume

18.41K

Avg. Volume

49.00K

Financials (TTM)

Gross Profit

-£71.37K

Operating Income

-£13.30M

EBITDA

-£14.37M

Operating Cash Flow

-£4.98M

Capital Expenditure

-£174.00K

Free Cash Flow

-£5.15M

Cash & ST Invst.

£19.39M

Total Debt

£667.94K

NuCana Plc Performance Analysis

NuCana Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 0N/A
20232023-12-31GBP 0N/A
20242024-12-31GBP 0N/A
20252025-12-31GBP 0N/A
NuCana Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
NuCana Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -3,775.53-29.5%
20232023-12-31GBP -3,266.68-13.5%
20242024-12-31GBP -1,635.98-49.9%
20252025-12-31GBP -17.20-98.9%
NuCana Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3098.1%
Q42025-12-31-783.3%
Q12026-03-31-61.1%
Q22026-06-3029.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£71.37K

N/A

Gross Margin

0.00%

N/A

Market Cap

$6.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$607.25K

N/A

Employees

11

N/A

Net Income

-£3.10M

+87.2%

EBITDA

-£3.38M

+70.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£19.39M

+129.6%

Total Debt

£667.94K

+333.7%

Accounts Receivable

£2.48M

-53.0%

Inventory

£0.00

N/A

Long Term Debt

£633.16K

+701.5%

Short Term Debt

£34.79K

-53.6%

Return on Assets

-37.96%

N/A

Return on Invested Capital

-63.87%

N/A

Free Cash Flow

-£1.93M

+57.6%

Operating Cash Flow

-£1.93M

+57.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CLGNCollPlant Biotechnologies Ltd.
$0.32-1.24%
MTVAMetaVia Inc.
$1.44-2.04%
LSTALisata Therapeutics, Inc.
$1.12+0.00%
GDTCCytoMed Therapeutics Limited
$0.90-0.11%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About NCNA

What is the current price of NuCana Plc?

NuCana Plc is trading at $1.53 per share.

What is the 52-week range for NuCana Plc?

Over the past 52 weeks, NuCana Plc has traded between $1.21 and $7.22.

How much debt does NuCana Plc have?

As of the most recent reporting period, NuCana Plc reported total debt of £891.91K.

How much cash does NuCana Plc have on hand?

NuCana Plc reported £25.89M in cash and cash equivalents in its most recent financial results.

What is NuCana Plc’s dividend yield?

NuCana Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services